Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells

Urology

Volumn 78, Issue 3, 2011, Pages 722.e1-722.e6

  Zhang, Xinji ^a   Shi, Xiaojun ^a   Li, Jinlong ^a   Hu, Zhiming ^a   Guo, Fangfang ^d   Huang, Xiao ^c   Zhang, Zhehuan ^a   Sun, Pengyu ^a   Jing, Yuming ^a   Gao, Jimin ^b   Tan, Wanlong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c TEMPLE UNIVERSITY   (United States)

^d Guangdong Women and Children's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 SURFACE MODIFIED MB49 CELL VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BIOTECHNOLOGY; BLADDER CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN IMMOBILIZATION; SKIN METASTASIS; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 80052316849     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.04.044     Document Type: Article

References (22)

1. S.A. Hussain, and N.D. James The systemic treatment of advanced and metastatic bladder cancer Lancet Oncol 4 2003 489 497 (Pubitemid 37009957)
2. A. Jemal, T. Murray, and E. Ward Cancer statistics CA Cancer J Clin 55 2005 10 30
3. L.L. Pisters, and L. Westney The management of locally recurrent invasive bladder cancer following radical cystectomy Semin Urol Oncol 14 1996 112 119 (Pubitemid 26154979)
4. I. Cagiannos, and C. Morash Surveillance strategies after definitive therapy of invasive bladder cancer Can Urol Assoc J 3 suppl 4 2009 S237 S242
5. F.M. Hofman, A. Stathopoulos, and C.A. Kruse Immunotherapy of malignant gliomas using autologous and allogenic tissue cells Anti Cancer Agents Med Chem 10 2010 462 470
6. R. Pul, D. Moharregh-Khiabani, and J. Skuljec Glatiramer acetate modulates TNF-alpha and IL-10 secretion in microglia and promotes their phagocytic activity J Neuroimmune Pharmacol 2010 Nov 3 Epub
7. N.P. Singh, E.S. Yolcu, and D.D. Taylor A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity Cancer Res 63 2003 4067 4073 (Pubitemid 36917929)
8. T.R. Malek, A. Yu, and L. Zhu IL-2 family of cytokines in T regulatory cell development and homeostasis J Clin Immunol 28 2008 635 639
9. X. Huang, H.S. Yu, and Z. Chen A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall Chin J Cancer 29 2010 611 616
10. R. Philip, B. Clary, and E. Brunette Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer Clin Cancer Res 2 1996 59 68
11. K.A. Tolba, W.J. Bowers, and S.P. Hilchey Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia Blood 98 2001 287 295
12. E. Galanis, R. Vile, and S.J. Russell Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors Crit Rev Oncol/Hematol 38 2001 177 192 (Pubitemid 32448027)
13. Z. Hu, W. Tan, and L. Zhang A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF J Cell Mol Med 14 2010 1836 1844
14. L. Zhang, Z. Hu, and P.P. Fa Preparation and characterization of SA-hIL2 fusion protein China Biotechnol 7 2009 12 16
15. J.T. Sosnowski, J.I. Dehaven, and D.R. Riggs Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma J Urol 146 1991 1164 1167
16. P.I. Haigh, L.A. Difrnzo, and G. Gammon Vaccine therapy for patients with melanoma Oncol Williston Park 13 1999 1561 1574
17. H. Li, H.J. Jiang, and M.Q. Ma Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine Cancer Biother Radiopharm 22 2007 790 798
18. K. Shimizu, R.C. Fields, and M. Giedlin Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines Proc Natl Acad Sci U S A 96 1999 2268 2273 (Pubitemid 29117903)
19. B.H. Yamane, J.A. Hank, and M.R. Albertini The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma Expert Opin Investig Drugs 18 2009 991 1000
20. B. Li, A. Simmons, and T. Du Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies Clin Immunol 133 2009 184 197
21. J.W. Fabre The allogeneic response and tumor immunity Nat Med 7 2001 649 652 (Pubitemid 32588008)
22. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu Rev Immunol 9 1991 271 296